
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
| Review | Status | Reviewer | Date | Notes |
|---|---|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. | ||
| clinical review | not_started | Awaiting clinician review; check the liver-mass work-up in a non-cirrhotic liver (biopsy rather than imaging criteria), the gallbladder primary, the staging laparoscopy, gemcitabine, cisplatin and durvalumab dosing and monitoring, hepatitis B monitoring rather than prophylaxis for resolved infection, and the timing of palliative care. | ||
| provenance review | not_started | Barth and Chen 2016 (PMC5009495), the Museum of Dr. Sun Yat-sen biography and chronology, Chow 2007 (The Hong Kong Practitioner), and the Tianjin University biography of Liu Ruiheng logged. The liver cancer and gallbladder cancer accounts are both recorded as R claims. | ||
| safe messaging review | not_started | A national founding figure; the modern episode adds no claim about his real health beyond the cited sources, his hepatitis B serology is labeled synthetic, and no decision or statement is attributed to his wife or other real people. His death is recorded as history only. |
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|---|---|---|
| 2026-06-01 Progress note 03 (C-CDA) | Glucose | Baseline, then with each pre-dose chemistry panel on durvalumab | Missed: today's pre-treatment panel was ordered as a renal panel with magnesium and did not include glucose. Glucose was 98 mg/dL at intake and he has no thirst or excess urination, so no harm is apparent. Corrective action: glucose added to the standing pre-dose order from the next draw |
| 2026-06-01 Progress note 03 (C-CDA) | Hearing (cisplatin) | Baseline before cisplatin, then by symptoms each cycle | Missed: no baseline audiogram before the first cisplatin dose; whispered-voice test normal today and no hearing symptoms. The lower 25 mg/m2 dose carries less risk; corrective action is to ask about hearing at each cycle and obtain an audiogram for any change |
| Visit | Type | Item | Status | Detail |
|---|---|---|---|---|
| 2026-05-18 Progress note 02 (C-CDA) | Referral | Multidisciplinary tumor board | Ordered | In two days |
| 2026-05-18 Progress note 02 (C-CDA) | Imaging | Staging laparoscopy | Ordered | In about ten days, with a port |
| 2026-05-18 Progress note 02 (C-CDA) | Laboratory | Comprehensive genomic profiling of tumor tissue | Ordered | Sent on the biopsy tissue |
| 2026-06-01 Progress note 03 (C-CDA) | Laboratory | Comprehensive genomic profiling of tumor tissue | Ordered | Pending |
| 2026-06-01 Progress note 03 (C-CDA) | Referral | Specialist palliative care | Referred | First visit next week |
| 2026-09-21 Progress note 06 (C-CDA) | Prevention | HIV screening | Ordered | Never tested; once-in-a-lifetime test drawn today with his agreement |
| Claim | Statement | Certainty |
|---|---|---|
| CLM-0010 | His fatal illness has long been described as liver cancer, the diagnosis taken from the findings at the laparotomy; the museum at his birthplace states that he died of liver cancer. | disputed |
| CLM-0011 | A limited autopsy at the Peking Union Medical College Hospital on March 13, 1925, by James R. Cash, reported adenocarcinoma of the gallbladder with obstruction of the cystic duct, direct extension to the liver and diaphragm, and metastases to the lungs, peritoneum, ileum and colon, with healed cholecystitis, gallstones, generalized arteriosclerosis, healed calcified tuberculosis of the lungs, emphysema, ascites and roundworm infestation. A 2016 review concludes that gallbladder adenocarcinoma, not a primary liver cancer, caused his death. | probable |
None.
None.
Every note in the record, with its type. All clinical content is synthetic.
| Date | Result | Value | Flag |
|---|---|---|---|
| 2026-05-04 | Hemoglobin | 12.6 g/dL (low) | Low |
| 2026-05-04 | Albumin | 3.4 g/dL (low) | Low |
| 2026-05-04 | Alkaline phosphatase | 212 U/L (high) | High |
| 2026-05-04 | AST | 48 U/L (high) | High |
| 2026-05-04 | CA 19-9 | 412 U/mL (high) | High |
| 2026-05-04 | CEA | 8.6 ng/mL (high) | High |
| 2026-06-01 | Hemoglobin | 12.2 g/dL (low) | Low |
| 2026-06-01 | Albumin | 3.4 g/dL (low) | Low |
| 2026-06-01 | Alkaline phosphatase | 236 U/L (high) | High |
| 2026-06-01 | AST | 52 U/L (high) | High |
| 2026-06-01 | CA 19-9 | 498 U/mL (high) | High |
| 2026-08-03 | Hemoglobin | 10.9 g/dL (low) | Low |
| 2026-08-03 | Alkaline phosphatase | 158 U/L (high) | High |
| 2026-08-03 | CA 19-9 | 168 U/mL (high) | High |
| 2026-10-26 | Hemoglobin | 10.7 g/dL (low) | Low |
| 2026-10-26 | Magnesium | 1.6 mg/dL (low) | Low |
| 2026-10-26 | Alkaline phosphatase | 141 U/L (high) | High |
| 2026-10-26 | CA 19-9 | 121 U/mL (high) | High |
| 2026-09-02 | White cells | 3.9 10*3/uL (low) | Low |
| 2026-09-02 | Neutrophils | 1.6 10*3/uL (low) | Low |
| 2026-09-02 | Hemoglobin | 10.6 g/dL (low) | Low |